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Phosphoinositide lipids generated at the cell membrane are a key component of a variety of signaling pathways. Among several inositol
phosphatases that regulate the availability of signaling phosphoinositide lipids, the type II SH2-domain-containing inositol 5-phosphatase (SHIP2;
approved gene symbol Inppl1) is believed to have multiple functions, including the regulation of insulin signaling and cytoskeletal functions. To
understand the function of SHIP2 in C2C12 muscle cells, we depleted SHIP2 through the use of RNA interference and analyzed the global effect
of SHIP2 depletion on gene expression using Affymetrix microarrays containing ∼45,000 mouse probe sets. Expression of SHIP2-targeting small-
hairpin RNA in differentiated C2C12 muscle cells led to >80% decrease in SHIP2 mRNA and 60–80% decrease in SHIP2 protein, which resulted
in significant gene expression changes linked to cytoskeletal functions, including altered expression of adducin-α, pallidin, stathmin-like-2, and
synaptojanin-2 binding protein. Insulin treatment of C2C12 muscle cells caused transcriptional changes associated with known signaling
pathways. However, SHIP2 depletion had no discernible effect on insulin-regulated gene expression. Taken together, our results suggest that
SHIP2 is involved in the regulation of cytoskeletal functions, but a large reduction of SHIP2 in C2C12 muscle cells is not sufficient to affect
insulin-mediated gene expression.
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from the cell membrane into the cytoplasm, phosphoinositol
lipids regulate a number of cellular processes, including
metabolism, cell growth, cell adhesion, and migration
(reviewed in [1]). The availability of the active metabolite
phosphatidylinositol-3,4,5-triphosphate [PI(3,4,5)P3] on the
plasma membrane is regulated by the lipid kinase phosphati-
dylinositol-3 kinase (PI3K) and members of the inositol
phosphatase family [2,3]. By hydrolyzing PI(3,4,5)P3, the⁎ Corresponding author. Fax: +1 617 665 8350.
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doi:10.1016/j.ygeno.2006.10.006inositol phosphatases limit the action of PI3K and negatively
regulate PI3K signaling.
The type II SH2-domain-containing inositol 5-phosphatase
(SHIP2; approved gene symbol Inppl1) is a 5′-phosphatase that
converts PI(3,4,5)P3 to PI(3,4)P2 and is believed to be a
negative regulator of insulin signaling. Overexpression of wild-
type and a dominant-negative mutant of SHIP2 in cultured
adipocytes and muscle cells implicated SHIP2 in the negative
regulation of insulin-mediated metabolic actions [4,5]. Further-
more, the expression of a SHIP2 dominant-negative mutant in
the liver of db/db mice resulted in enhanced insulin signaling
and ameliorated hyperglycemia and hyperinsulinemia [6].
However, Tang et al. found that reducing SHIP2 levels by
RNA interference (RNAi) in cultured adipocytes failed to affect
insulin-regulated events [7]. Homozygous deletion of SHIP2 in
mice led to severe hypoglycemia and perinatal death, while the
271C. Huard et al. / Genomics 89 (2007) 270–279heterozygous mice exhibited increased insulin sensitivity [8,9].
Nevertheless, the interpretation of this study was complicated
by the fact that these SHIP2-deficient mice also contained a
deletion of the adjacent homeobox gene Phox2a. An indepen-
dent study on SHIP2-deficient mice linked SHIP2 functions to
obesity but not insulin signaling [10]. Other studies associated
SHIP2 with diabetes, but the underlying molecular mechanisms
remained unclear [11–14]. Aside from its role in insulin
signaling SHIP2 also plays a role in the regulation of
cytoskeletal functions, cell adhesion, endocytosis, cell cycle,
cell growth, apoptosis, and M-CSF signaling [15–21]. It is
likely that SHIP2 can modulate multiple functions depending
on the cell type and signaling pathways.
SHIP2 is abundantly expressed in the skeletal muscle [22],
but its function in this tissue has not been definitively
established. A key question is to what extent SHIP2 regulates
insulin signaling in muscle. Skeletal muscle is one of the
primary tissues that mediate the metabolic effects of insulin
via glucose uptake and removal. The disruption of these
functions is associated with insulin resistance in type II
diabetes mellitus. A major means by which insulin modulates
metabolism is through the regulation of gene expression
(reviewed in [23,24]). Several recent studies have demon-Fig. 1. SHIP2 reduction in C2C12 muscle cells. C2C12 myoblasts were differentia
Seventy-two hours postinfection, cells were harvested and SHIP2 mRNA levels we
SHIP2, PTEN, and actin protein levels were determined by Western analysis. In (B), t
“sh” denotes the average of six SHIP2-depleted samples combining triplicate sh942
combining triplicate nscDI and triplicate nscVIII samples. The numbers 0, 2, and 6 in
set at 100% and the relative levels of the other samples were determined and plottestrated that microarray technology is a powerful tool to
examine the global transcriptional effect of insulin on skeletal
muscles [25–28]. To investigate the effect of SHIP2 inhibition
on gene expression in C2C12 muscle cells in the presence or
absence of insulin, we used RNAi-mediated gene silencing to
deplete specifically SHIP2 and performed microarray analysis.
Reduction of 60–80% of SHIP2 in unstimulated C2C12
myotubes led to transcriptional changes in several genes
regulating cytoskeletal functions and endocytosis. Interest-
ingly, this level of SHIP2 depletion did not significantly
modulate insulin-stimulated gene expression. Our results
suggest that SHIP2 may regulate cytoskeletal functions and
endocytosis and reveal that a depletion of most of SHIP2
does not alter insulin-mediated gene expression in C2C12
muscle cells.
Results
Expression profiling analysis to assess gene expression
changes in SHIP2-depleted C2C12 myotubes
To investigate the specific functions of SHIP2 in C2C12
muscle cells, we depleted endogenous SHIP2 via adenoviralted for 4 days before infection with nsc control or SHIP2 shRNA adenovirus.
re determined by (A) TaqMan real-time PCR and (B) microarray analysis. (C)
he microarray frequency data in parts per million for each sample were retrieved.
and triplicate sh2247 samples. “nsc” denotes the average of six control samples
dicate hours of insulin treatment. The frequency data for “nsc 0” were arbitrarily
d in the graph.
Table 1A
List of signaling pathways significantly affected (p value <0.05) by insulin
stimulation from analysis of the 1944 insulin-regulated probe sets by Ingenuity
Pathway Analysis (IPA)
Metabolic and signaling pathways No. of genes p value
PDGF signaling 17 2.35×10–5
Ephrin receptor signaling 27 3.22×10–5
IGF-1 signaling 19 4.08×10–5
PI3K/AKT signaling 22 1.03×10–4
ERK/MAPK signaling 27 1.34×10–4
Integrin signaling 32 3.96×10–4
VEGF signaling 16 1.14×10–3
Hypoxia signaling in the cardiovascular system 12 1.59×10–3
JAK/Stat signaling 12 2.93×10–3
Neuregulin signaling 15 3.73×10–3
EGF signaling 10 5.12×10–3
Cell cycle G1/S checkpoint regulation 11 7.40×10–3
PTEN signaling 14 1.08×10–2
IL-6 signaling 14 1.08×10–2
SAPK/JNK signaling 14 1.57×10–2
p38 MAPK signaling 12 2.49×10–2
Glycolysis/gluconeogenesis 16 2.62×10–2
Insulin receptor signaling 17 3.93×10–2
IL-10 signaling 11 4.42×10–2
A total of 1654 genes out of the 1944 probe sets were found in the IPA database.
Table 1B
Promoter analysis of the 1413 insulin-responsive probe sets consisting of 589
up-regulated and 425 down-regulated genes
IRE Consensus sequence No. of
promoters
analyzed
No. of
promoters
containing
IRE
AP-1 motif TGA(G/C)TCA 589 88
E-box motif CANNTG 589 576
Ets motif (C/A)GGA(A/T) 589 589
GAPDH-IRE-
A-like motif
CCCGCCTC 589 145
SRE motif CC(A/T)6GG 589 37
SREBP motif ATCACCCCAC 589 2
TTF-2 motif C(T/A)(A/G)A(A/G)(C/A)AAACA 589 26
PEPCK-like
motif
T(G/A)TTT(T/G)(G/T) 425 338
Seven consensus-positive IREs and one consensus-negative IRE (PEPCK-like
motif) were used to query the genes.
272 C. Huard et al. / Genomics 89 (2007) 270–279delivery of expressed small hairpin RNA (shRNA). We selected
2 independent SHIP2-depleting shRNAs as well as 2 non-
specific control (nsc) shRNAs to evaluate the specific effects of
RNA interference while minimizing off-target effects. After
testing 10 SHIP2-targeting shRNAs, we selected 2 (sh942 and
sh2247) based on their effective reduction of SHIP2 mRNA in
mouse AML12 cells (data not shown). Adenovirus expressing
these 2 SHIP2 shRNAs and 2 nsc shRNAs (nscDI and nscVIII)
were generated and SHIP2 knockdown was confirmed in
AML12 cells (data not shown).
Expression profiling analysis was used to assess globally the
effect of SHIP2 reduction on insulin-mediated gene expression
in C2C12 myotubes. Differentiated C2C12 myotubes were
infected in triplicate with adenovirus expressing each of the two
SHIP2 shRNAs or the two nsc shRNAs (referred to as SHIP2-
depleted or control cells, respectively). To study the insulin
response of control or SHIP2-depleted cells, serum-starved
C2C12 myotubes were treated with 10 nM insulin for 0, 2, and
6 h. At the end of each treatment, total RNA was isolated for
each sample prior to expression profiling analysis using
Affymetrix microarrays. The reduction of SHIP2 mRNA was
confirmed by TaqMan real-time PCR analysis with mRNA from
untreated SHIP2-depleted or control cells. As shown in Fig. 1A,
the SHIP2 shRNA reduced SHIP2 mRNA level by 82% for
sh942 and 88% for sh2247. Furthermore, microarray data
showed that SHIP2 expression was not affected at any time by
insulin treatment (Fig. 1B). In addition, parallel samples were
used to confirm the reduction of SHIP2 protein in SHIP2-
depleted cells. Western blot analysis revealed that SHIP2
proteins were decreased by 62% for sh942 and 78% for sh2247
compared to the controls (top in Fig. 1C). The expression of
SHIP2 shRNA did not affect the protein levels of PTEN and
actin (middle and bottom, Fig. 1C).Insulin elicits expected gene expression changes in C2C12
muscle cells
The Affymetrix MOE430 2.0 microarray used in our study
interrogates the expression levels of 45,101 probe sets. For
reference, a probe set denotes a sequence corresponding to a
fragment of a specific gene on the microarray. Different probe
sets can correspond to distinct sequences of the same gene. We
first sought to confirm that the insulin treatment was eliciting
the expected transcriptional responses in the muscle cells. For
this purpose, we generated an insulin-responsive signature gene
set using only the control samples. After applying the data
reduction filter (described under Materials and methods) to
remove low-expressed genes, we performed a one-factor
ANOVA on the normalized frequency data of the untreated
and insulin-treated control samples. We identified 1944 probe
sets significantly changing (p value ≤0.0001 and FDR≤10%)
at 2 or 6 h of insulin treatment compared to untreated samples
(i.e., 0 h insulin treatment). These 1944 insulin-responsive
probe sets were subjected to ingenuity pathway analysis (IPA)
to assess the affected signaling pathways. IPA is an algorithm
designed to compute multiple networks of pathways using the
Ingenuity Pathways Knowledge Base, which contains over 1
million findings curated from peer-reviewed journal articles
(e.g., [29]). Of a total of 137 signaling pathways in the IPA
database, 19 canonical pathways were found to be significantly
associated with the insulin-regulated genes (Table 1A). Both
insulin receptor signaling and PI3K/AKT signaling pathways
were identified. The majority of the remaining pathways were
known to be modulated by insulin, which included PTEN
signaling, ERK/MAPK signaling, p38 MAPK signaling,
glycolysis/gluconeogenesis, and several growth factor signaling
pathways (Table 1A; also see Supplemental Table 1 for a
complete list of genes from each signaling pathway).
To characterize further the genes significantly affected by
insulin, we performed promoter analysis on the 1944 insulin-
responsive probe sets. After unknown ESTs were removed from
this list, the remaining 1413 probe sets, corresponding to 1189
273C. Huard et al. / Genomics 89 (2007) 270–279unique genes, were divided into 682 up-regulated and 507
down-regulated genes (relative to 0 h insulin treatment). From
these gene lists, the promoter sequences for 589 up-regulated
and 425 down-regulated genes were retrieved from DBTSS and
were queried for the presence of seven positive insulin-response
elements (IREs) (top seven IREs in Table 1B) and one negative
IRE (“PEPCK-like motif,” Table 1B) [24]. The majority of the
genes retrieved from the DBTSS database contained at least one
putative IRE in their proximal promoter region (Table 1B; see
Supplemental Table 2 for complete lists of genes). In addition,
we searched for overrepresented regulatory motifs in the
promoters of the 589 up-regulated and 425 down-regulated
genes. The putative binding sites for two transcription factors,
activator protein 1 and serum response factor, whose binding
site sequences correspond to IREs of AP-1 motif and serum-Fig. 2. Unsupervised hierarchical clustered display of insulin-responsive probe sets i
data were generated from RNA isolated from control C2C12 muscle cells treated with
combining triplicate sh942 and triplicate sh2247 samples. “nsc” denotes the average
The numbers 0, 2, and 6 indicate hours of insulin treatment. Transcripts with low ex
performed on the remaining probe sets to identify probe sets that showed significant
identified 1944 probe sets significantly regulated by insulin treatment. Each probe set
a column. Each cluster indicates genes induced (red) and repressed (blue). The dat
insulin-regulated genes.response element, respectively, were significantly overrepre-
sented (p value <0.01) in the promoter regions of the insulin up-
regulated genes compared to the background genes that were
not regulated by insulin. Together, the IPA and promoter
analysis demonstrate that insulin stimulation of C2C12 muscle
cells elicited the expected gene expression changes.
SHIP2 reduction does not affect insulin-mediated gene
expression in C2C12 myotubes
To determine the effect of SHIP2 reduction on insulin-
mediated transcriptional response, the 1944 insulin-responsive
probe sets were used to query gene expression changes
associated with SHIP2 depletion. Using unsupervised hierarch-
ical Eisen clustering analysis, we found that SHIP2-depletedn differentiated C2C12 myotubes with or without SHIP2 depletion. Microarray
insulin for 0, 2, or 6 h. “sh” denotes the average of six SHIP2-depleted samples
of six control samples combining triplicate nscDI and triplicate nscVIII samples.
pression levels (<5 ppm) and low-confidence calls were removed. ANOVAwas
changes at 2 or 6 h compared to 0 h. An additional filter imposing a 10% FDR
is represented by a single row and each sample, in triplicate at each time point, by
a indicate that SHIP2 reduction does not significantly alter the transcription of
Table 2
Results of two-factor ANOVA of gene expression in SHIP2-depleted and
insulin-stimulated C2C12 muscle cells
p value FDR (maximum value) No. of genes
SHIP2 status 0.05 31% 2939
0.01 14% 1298
5.05×10–3 10% 969
Insulin effect 0.05 9% 8516
0.01 2% 6802
5.55×10–2 10% 8629
Interaction SHIP2
status× insulin effect
0.05 99% 939
0.01 99% 174
– 10% 0
Statistical analysis and FDR calculations are described under Materials and
methods.
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insulin treatment time point (0, 2, and 6 h) but did not segregate
based on SHIP2 expression levels (Fig. 2), indicating that
insulin treatment but not SHIP2 depletion determined the
sample clustering.
Another independent analytical approach was carried out to
determine the effects of SHIP2 depletion on insulin-mediated
gene expression changes. In this approach, we performed a two-
factor ANOVA on log-transformed frequencies across all
control and SHIP2-depleted samples. The Benjamini and
Hochberg (BH) procedure for controlling false discovery rate
(FDR) was also applied. By selecting the main effect of time
from the two-factor ANOVA results, the expression levels of
8629 genes were found to be significantly changed (p value
≤5.55×10−2 and FDR≤10%) in the cells treated with 10 nM
insulin at either 2 or 6 h compared to untreated cells (i.e., 0 h
insulin treatment; “Insulin effect” in Table 2). The results from
the two-factor ANOVA performed across all control and SHIP2-
depleted samples were also used to identify transcriptional
targets affected by both SHIP2 reduction and insulin stimula-
tion. As shown in Table 2 (“Interaction SHIP2 status× insulin
effect”), we did not identify any probe sets that were induced or
repressed in a statistically significant way (at an FDR≤10%),
suggesting that SHIP2 reduction did not significantly affect
insulin-mediated transcription. Consistent with our previous
analysis, this analytical approach failed to identify any insulin-
modulated genes whose expression was affected by SHIP2
depletion. Taken together, we conclude that in C2C12Table 3
List of biological functions significantly affected by SHIP2 reduction (p value <0.05)
analysis
Function No. of global analysis
Skeletal and muscular system development and function 41
Tissue morphology 34
Cellular assembly and organization 36
Posttranslational modification 51
Molecular transport 21
Protein trafficking 21
Tissue development 29
The complete list of pathways associated with each function is provided as supplemmyotubes, up to 80% reduction in SHIP2 protein has no
discernible effect on insulin-mediated gene expression.
SHIP2 depletion affects the expression of cytoskeletal and
endocytosis genes
By selecting the main effect of SHIP2 status from the two-
factor ANOVA described previously, we identified a subset of
969 genes (corresponding to 1086 probe sets) significantly
changing (p value≤0.005 and FDR≤10%) as a result of SHIP2
depletion (Table 2, “SHIP2 status”). IPA was applied to these
969 genes to determine the biological processes associated with
the gene expression changes. As shown in Table 3, the
biological functions significantly associated with these
SHIP2-dependent genes were linked to cytoskeletal regulation,
including muscular development, tissue morphology, cellular
assembly/organization, molecular transport, and protein traf-
ficking (representative genes for each function shown in Table
3; also see Supplemental Table 3 for a complete gene list).
Furthermore, supervised hierarchical clustering of the 1086
SHIP2-dependent probe sets showed that 24 probe sets
coclustered with SHIP2 (named INPPL1) in cells not treated
with insulin (Table 4 and Fig. 3). The expression of these genes
was significantly decreased in SHIP2-depleted cells compared
to the control cells. Among these 24 probe sets, 9 corresponded
to novel genes with unknown functions. Based on PubMed
(www.ncbi.nlm.nih.gov), 5 of the remaining 15 probe sets
represented 4 genes encoding proteins that function in
cytoskeletal regulation and intracellular trafficking (indicated
by green arrows in Fig. 3): pallidin-1, synaptojanin binding
protein-1 (SYNJ2BP), stathmin-like-2 (STMN2), and adducin-
α [34–37]. Adducin-α was represented by 2 individual probe
sets and showed the most robust changes. Quantitative PCR
analysis confirmed the reduction of its mRNA upon SHIP2
depletion (Fig. 3B). These results suggest a role for SHIP2 in
the regulation of actin cytoskeleton and endocytosis in muscle
cells.
Discussion
The lipid phosphatase SHIP2 functions in a variety of
signaling pathways by controlling the availability of the active
metabolite PI(3,4,5)P3. The role of SHIP2 in muscle cells has
not been well defined. In this study, we analyzed the globalby analysis of 969 SHIP2-affected genes (see Table 1) using ingenuity pathway
genes p value Representative genes
1.67×10–6–4.64×10–2 ACTN2, MYOM2, MYOD1, VCAM1
1.67×10–6–4.64×10–2 MYL9, NEB, TCAP, TPM2
2.34×10–5–4.81×10–2 MAPRE1, PLDN, VAMP3
4.07×10–4–4.26×10–2 NEDD4, DAPK2, MYLK
1.15×10–3–3.48×10–2 SSR1, SSR2, COG2
1.15×10–3–3.48×10–2 RAN, TNPO1
1.59×10–3–4.70×10–2 FZD5, F2, NRP1
ental data.
Table 4
Genes coclustering with SHIP2 expression
Qualifier Gene symbol Gene name Accession No. Fold change
(nsc/sh)
p value
(treatment)
1429556_at 2610024B07Rik RIKEN cDNA 2610024B07 gene BM214769 1.36 3.70×10–9
1452901_at 3526402H21Rik RIKEN cDNA 3526402H21 gene AK014391 1.14 2.64×10–3
1431774_a_at (4930404J24Rik, 4930456J16Rik) RIKEN cDNA 4930456J16 gene AK015083 1.19 4.30×10–3
1433860_at 6030458C11Rik RIKEN cDNA 6030458C11 gene BB126127 1.21 5.57×10–7
1454709_at 9630015D15Rik RIKEN cDNA 9630015D15 gene BG075363 1.12 1.01×10–3
1450054_at ADD1 Adducin 1 (α) BF140063 1.42 8.41×10–15
1420953_at ADD1 Adducin 1 (α) BF140063 1.76 2.47×10–11
1445888_x_at PARP3 Poly(ADP-ribose) polymerase family, member 3 AW990611 1.35 9.00×10–6
1451202_at (C330007P06Rik, na) RIKEN cDNA C330007P06 gene BC021479 1.14 1.49×10–3
1460716_a_at (AI225912, Cbfb) Core binding factor β NM_022309 1.45 3.20×10–10
1455389_s_at (2310051F07Rik, Chrac1) RIKEN cDNA 2310051F07 gene AI415636 1.25 1.55×10–6
1460278_a_at D15WSU75E DNA segment, Chr 15, Wayne State University 75, expressed NM_134095 1.16 1.36×10–3
1455134_at (A630051L19Rik,
AI957324, D730040F13Rik)
RIKEN cDNA A630051L19 gene AF031164 1.45 1.48×10–6
1438702_at FLRT2 Fibronectin leucine-rich transmembrane protein 2 BG075699 1.23 7.38×10–4
1439029_at GPT2 Glutamic pyruvate transaminase (alanine aminotransferase) 2 BG069993 1.30 3.40×10–3
1453995_a_at HTF9C HpaII tiny fragments locus 9c AK017819 1.16 3.80×10–3
1460394_a_at SHIP2 (Inppl1) Inositol polyphosphate phosphatase-like 1 BB769433 3.72 1.34×10–13
1417349_at PLDN Pallidin NM_019788 1.16 1.05×10–5
1428119_a_at RAP2C RAP2C, member of RAS oncogene family AK008416 1.28 1.64×10–7
1423280_at STMN2 Stathmin-like 2 BM115022 1.11 1.51×10–3
1435870_at SYCP3 Synaptonemal complex protein 3 BM899344 1.15 1.08×10–3
1448853_at SYNJ2BP Synaptojanin 2 binding protein NM_025292 1.20 3.61×10–5
1448880_at UBE2L3 Ubiquitin-conjugating enzyme E2L 3 BG066549 1.13 3.59×10–3
1436788_at (Acp2, Ddb2) Damage-specific DNA binding protein 2 AI131584 1.14 1.65×10–4
1439035_at ZFP322A Zinc finger protein 322a BG075830 1.23 3.45×10–3
275C. Huard et al. / Genomics 89 (2007) 270–279transcriptional changes in C2C12 myotubes in response to
SHIP2 depletion and identified expression changes in genes
regulating cytoskeletal organization and endocytosis. Further-
more, SHIP2 depletion had little effect on the insulin-mediated
gene expression profile. To our knowledge, this is the first
microarray study to analyze the global transcriptional changes
in insulin-treated C2C12 muscle cells in response to SHIP2
reduction.
Differentiated C2C12 muscle cells are a model cell system
for studying insulin signaling and metabolism (e.g., [30,31]).
We found that these cells generated extensive transcriptional
changes in response to insulin treatment. Using IPA and
promoter analysis, we confirmed that insulin treatment elicited
the expected transcriptional responses in our cellular system.
Although this study was not specifically designed to investigate
the modulation of gene expression by insulin in C2C12 muscle
cells, our microarray results provide valuable reference data on
insulin-stimulated C2C12 muscle cells, including a signature
insulin-responsive gene set and a list of genes that contain
various IREs in their promoter regions.
Currently it is not clear to what extent SHIP2 regulates
insulin signaling in muscle cells. Overexpression studies
showed that SHIP2 negatively regulated insulin-induced
glycogen synthesis in the rat L6 myotubes [4]. While the
skeletal muscle of SHIP2 knockout mice exhibited increased
Akt phosphorylation upon insulin stimulation, the SHIP2
knockout mice did not show significantly enhanced insulin
sensitivity [10]. Using transcriptional profiling, we examined
whether SHIP2 depletion led to enhanced insulin response attranscriptional levels in C2C12 muscle cells. Under our
experimental conditions, we found that SHIP2 depletion did
not cause gene expression changes indicative of enhanced
insulin action. There are several possibilities that could lead to
our observations. First, SHIP2 may not regulate insulin-
dependent transcriptional changes but instead may regulate
posttranscriptional events. Second, although SHIP2 was
reduced to up to 80% of its basal levels in our study, the
residual SHIP2 may be sufficient to regulate insulin signaling
negatively. Third, since SHIP2 regulates only PI3K-dependent
insulin signaling events, other PI3K-independent pathways may
function to regulate insulin-mediated transcriptional changes.
Fourth, other lipid phosphatases such as PTEN may provide
redundant functions when the SHIP2 level is reduced. Future
experiments will focus on addressing these possibilities.
Two findings in our study led us to hypothesize a functional
role for SHIP2 in the regulation of cytoskeletal functions in
muscle. First, the IPA revealed that the biological functions
significantly associated with SHIP2 depletion were linked to
cytoskeletal regulation. Second, SHIP2 depletion resulted in
significant changes in the expression of four genes involved in
cytoskeletal functions. Among these four genes coclustering
with SHIP2 reduction, adducin-α is a subunit of adducin, which
functions to cap actin filaments and recruits spectrin to the ends
of filaments [32]. Pallidin is capable of associating with actin
filaments and may function to mediate the biogenesis of
lysosome-related organelles [33]. All four genes [adducin,
SYNJ2BP (also named ARIP2), pallidin, and stathmin] play a
role in endocytosis and/or trafficking of intracellular vesicles
Fig. 3. SHIP2 reduction alters the expression of cytoskeleton-associated genes. (A) Supervised hierarchical clustering was performed on the 1086 SHIP2-dependent
probe sets (Table 1) as well as all experimental samples. Based on gene expression patterns, 24 probe sets were found to cocluster with SHIP2 (named INPPL1 as
indicated by yellow arrow). Green arrows point to five probe sets corresponding to four genes that have reported functions in vesicle formation and cytoskeletal
organization. “sh” denotes the average of six SHIP2-depleted samples combining triplicate sh942 and triplicate sh2247 samples. “nsc” denotes the average of control
samples combining triplicate nscDI and triplicate nscVIII samples. The numbers 0, 2, and 6 indicate hours of insulin treatment. (B) Expression of adducin-αmRNA by
TaqMan real-time quantitative PCR confirmed the microarray data. Bars represent SEM and *p<0.05.
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consistent with recent findings that link SHIP2 function to the
regulation of the cytoskeleton. Prasad et al. reported that SHIP2
regulated the cytoskeleton organization and endocytosis of
EGFR in HeLa cells [19]. SHIP2 was shown to bind directly to
several proteins involved in the structural maintenance and
remodeling of the actin cytoskeleton, including vinexin, shc,
p130Cas, and actin-binding protein filamin C [15–18]. The
possible mechanisms by which SHIP2 can regulate actin
remodeling include modulation of PI3K signaling through
dephosphorylation of PI(3,4,5)P3 and possibly PI(3,4)P2 and/or
functioning as a scaffolding protein for signaling and structural
molecules [18]. SHIP2 may play a role in endocytosis through
phosphoinositol regulation of small GTP proteins of the Rab
family or through cross talk with Rho family members [19].
Since it is most likely that SHIP2 regulates cytoskeletal
functions through posttranslational mechanisms, the gene
expression changes we observed in our study may not be a
direct transcriptional consequence of SHIP2 depletion but may
rather reflect a cellular feedback response. It is noteworthy that
the cytoskeletal gene expression changes were captured by
∼72 h post-SHIP2 depletion, which may reflect any adaptivechanges to the cytoskeletal effects as a result of SHIP2
reduction. Our results are reminiscent of a recent microarray
study showing that gene expression changes in the skeletal
muscle of X-linked myotubular myopathy patients have been
linked to the cytoskeletal remodeling of the cells [38].
Intriguingly this disease is mapped to mutations in the
myotubularin (MTM1) gene, whose protein product is a lipid
phosphatase implicated in structural maintenance of muscle
cells and membrane functions [39,40]. Future work will be
required to examine the functional changes in cytoskeletal
architecture and endocytosis in response to SHIP2 depletion in
cultured muscle cells. In addition, a close examination of
muscle morphology and functions in SHIP2-deficient mice
would help to establish the function of SHIP2 in the regulation
of cytoskeletal functions.
In summary, we have used RNAi and expression profiling
analyses to examine the function of SHIP2 in C2C12 muscle
cells. Our results suggest that SHIP2 is involved in the
regulation of cytoskeletal organization and endocytosis. Future
studies will focus on unraveling the molecular mechanism by
which SHIP2 functions in cytoskeletal regulation and
endocytosis.
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Generation of shRNA expression vectors
To construct the shRNA expression vector, pAdori1-5, the CVM promoter
in the pAdori vector [41] was replaced with the human U6 promoter, which
was generated by PCR amplification. The pSilencer 2.0-U6 vector (Ambion,
Inc., Austin, TX, USA) was used as the template. The sequences of the
primers were 5′-ATCGATAGATCTCCCAGTGGAAAGACGCGCAGGCA-3′
and 5′-ATCGATAAGCTTGTACTAGTGTGAATTCCGCGTCCTTTCCA-
CAAGATATA-3′.
An shRNA design software developed by the Bioinformatics Group at
Wyeth was employed to identify candidate target sequences in mouse SHIP2
and to design hairpin siRNA-encoding DNA oligonucleotides. Candidate
sequences were used to query the mouse genome to eliminate sequences with
significant homology to other mouse genes. Two nonspecific control sequences,
nscDI and nscVIII, which shared no homology to any reported mouse sequences
by BLAST analysis, were selected. The SHIP2-targeting and the nonspecific
control sequences were sh942, GTGAAGCTGGATGTAACAC; sh2247,
GAGTTTGAGAGTATCGAAG; nscDI, CGAGTCGCGTTTGCGACTG; and
nscVIII, ACTCTATCTGCACGCTGAC.
Each siRNA sequence was converted to shRNA with the loop sequence
CTTCCTGTCA and cloned as double-stranded DNA oligonucleotides into the
EcoRI and HindIII sites of pAdori1-5. The resulting plasmids were verified by
sequencing.
Generation of adenoviruses
Each pAdori1-5 shRNA-expressing plasmid was digested with AscI and
BstZ17I and the fragment containing shRNA and adenoviral genomic sequence
was isolated. Recombinant adenoviral genomic DNAwas linearized with PacI.
The pAdori1-5 DNA fragment was cotransfected with adenoviral genomic DNA
into early passage 293 cells using Fugene 6 (Roche Diagnostics Corp.,
Indianapolis, IN, USA). Ten to fourteen days posttransfection, the recombinant
adenovirus was harvested and subjected to another two rounds of amplification
in 293 cells. The resulting virus was used to infect 293 cells at a large scale
followed by purification by CsCl gradient ultracentrifugation.
Cell culture, transfection, and adenoviral infection
C2C12 myoblasts were obtained from the American Type Culture
Collection (Manassas, VA, USA) and cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% FBS, penicillin/streptomycin, and L-
glutamine (all reagents from Invitrogen, Inc., Carlsbad, CA, USA). Confluent
cells were differentiated in DMEM supplemented with 2% horse serum for
4 days. After cells were fully differentiated, they were infected with adenovirus
at a multiplicity of infection of 500 plaque-forming units per cell. The
subsequent TaqMan and Western analyses were done 72 h postinfection. For
insulin stimulation, the cells were cultured for 16 h in serum-free DMEM prior
to treatment with 10 nM insulin.
TaqMan real-time quantitative PCR
RNAwas isolated and purified from C2C12 myotubes using an RNeasy kit
(Qiagen, Inc., Valencia, CA, USA) according to the manufacturer’s instructions.
Using an ABI Prism 7000 sequence detection system (PE Applied Biosystems,
Foster City, CA, USA), SHIP2 and adducin-α mRNA levels were measured by
TaqMan real-time quantitative PCR. Reactions were performed with a mixture
of TaqMan PCRMaster Mix (PE Applied Biosystems), mouse SHIP2 Assay-on-
Demand TaqMan reagent (PE Applied Biosystems), reverse transcribed total
RNA (TaqMan Reverse Transcription Reagents Kit first-strand cDNA synthesis
system protocol; Roche), and eukaryotic 18S rRNA endogenous control (VIC/
TAMRA; PE Applied Biosystems). The thermal cycler conditions were as
follows: 2 min at 50°C, followed by 10 min at 95°C, followed by two-step PCR
for 40 cycles of 95°C for 15 s, 60°C for 1 min. Threshold cycle (Ct) values were
obtained for mouse SHIP2 and the values were normalized relative to the 18S
internal control. TaqMan real-time quantitative PCR was performed in duplicateand the average values were used for quantification. Data analysis was
performed as recommended by the manufacturer using the ΔΔCt method (PE
Applied Biosystems).
Western analysis
Protein extracts were prepared from C2C12 myotubes by lysing cells in lysis
buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% Triton X,
5 mM DTT) supplemented with a protease inhibitor tablet (Roche). Cell lysates
were subsequently cleared by centrifugation. The supernatant was collected and
used for Western analysis. To detect SHIP2, an anti-SHIP2 antibody was raised
against the sequence PRGPSDYGRPLSFRIRESIQED, which corresponds to
amino acids 1155–1179 of mouse SHIP2 [10] (Abgent, Inc., San Diego, CA,
USA). Detection of PTEN and actin was achieved with an anti-PTEN polyclonal
antibody (Cell Signaling Technology, Inc., Danvers, MA, USA) and an anti-
actin polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA), respectively.
Gene expression profiling
Double-stranded cDNA was synthesized from 5 μg of total RNA using the
SuperScript System (Invitrogen). The cDNAwas purified by filtration through a
multiscreen filter plate (Millipore, Billerica, MA, USA) and transcribed in vitro
using T7 RNA polymerase (Epicentre, Madison, WI, USA) and biotinylated
nucleotides (Perkin–Elmer, Boston, MA, USA). Hybridization buffer containing
spike pool reagent was added to each of the fragmented cRNA mixtures and each
sample was hybridized to the Mouse Genome 430 2.0 array (Affymetrix, Santa
Clara, USA) at 45°C for 18 h as recommended by the manufacturer. The
hybridized chips were washed and stained using Affymetrix Fluidics Station 450
and EukGE-WS2v4_450 as recommended by the manufacturer. The staining was
performed using a streptavidin–phycoerythrin conjugate (SAPE; Molecular
Probes, Eugene, OR,USA), followed by biotinylated antibody against streptavidin
(Vector Laboratories, Burlingame, CA, USA) and then SAPE. The arrays were
scanned using an Affymetrix Genechip Scanner and .cel files were generated with
Affymetrix Microarray Suite 5.0 (MAS 5.0) software. The frequency values were
generated using the scaled frequency normalization method [42] in which the
average differences for 11 control cRNAswith known abundance spiked into each
hybridization solution were used to generate a global calibration curve. This
calibration curve was then used to convert average difference values for all
transcripts to frequency estimates (in ppm) ranging from 1:300,000 (∼3 ppm) to
1:1000 (1000 ppm). All transcripts with maximum expression level less than
5 ppm across all samples and assigned an absent confidence call by the MAS 5.0
software were not included in the analysis (data reduction filter).
Statistical analysis
ANOVA (analysis of variance) was performed on log-transformed
frequencies. A single-factor ANOVA was used to identify a signature set of
insulin-responsive genes. For those data for which there were multiple
comparisons, a two-factor ANOVA was performed to determine the probe sets
dependent on both SHIP2 reduction and insulin stimulation.
Multiple testing corrections were resolved by applying the BH procedure for
controlling FDR to the set of raw p values derived from ANOVA. The biological
implication of the genes showing significant changes at 10% FDR was
investigated.
Unsupervised and supervised hierarchical clustering of genes and/or arrays
based on similarity of expression profiles was done using the procedure of Eisen
et al. [43]. The transcripts passing our data reduction filter (as described above)
were used. The expression data were log transformed and standardized to have a
mean value of 0 and a variance of 1, and hierarchical clustering results were
generated using average linkage clustering with an uncentered correlation
similarity metric.
Ingenuity pathway analysis
Data were analyzed through the use of ingenuity pathway analysis
(Ingenuity Systems: www.ingenuity.com). The functional analysis of IPA was
278 C. Huard et al. / Genomics 89 (2007) 270–279used for the identification of biological functions and/or diseases that were most
significant to the data set. Genes from the data set that met the ANOVA p-value
cutoff and were associated with biological functions and/or diseases in the
Ingenuity Pathways Knowledge Base were considered for the analysis. Fisher’s
exact test was used to calculate a p value determining the probability that each
biological function and/or disease assigned to the data set was due to chance
alone. Canonical pathways analysis identified the pathways from the ingenuity
pathways analysis library of canonical pathways that were most significant to
the data set. Genes from the data set that met the ANOVA p-value cutoff of 0.05
and were associated with a canonical pathway in the Ingenuity Pathways
Knowledge Base were considered for the analysis. The significance of the
association between the data set and the canonical pathway was measured in two
ways: (1) The ratio of the number of genes from the data set that map to the
pathway divided by the total number of genes that map to the canonical pathway
was displayed. (2) Fisher’s exact test was used to calculate a p value determining
the probability that the association between the genes in the data set and the
canonical pathway was explained by chance alone.
Promoter analysis of insulin-responsive genes
To analyze the IREs, the promoter sequences (1000 bp upstream and 200 bp
downstream of the transcription start site (TSS) defined by DBTSS [44]) for 589
of 682 insulin-induced genes and 425 of 507 insulin-repressed genes were
retrieved from the DBTSS database. For genes with alternative promoters, we
used the following criteria for unique promoter selection. First, the promoter
with the highest number of confident clone supports was selected. Second, for
promoters with the same number of confident clone supports, the one with the
most 5′ TSS position was selected. Seven positive insulin-response element
consensus sequence patterns [24] were searched in the promoter regions of the
insulin-induced genes and one negative insulin-response element consensus
sequence pattern [24] was searched in the promoter regions of the insulin-
repressed genes. The Patsearch program from Professional TRANSFAC 10.1
[45] was used for the pattern match with the mismatch parameter set at 0.
For motif overrepresentation analysis, the promoter sequences for 589 of
682 insulin-induced genes and 425 of 507 insulin-repressed genes were
retrieved from the DBTSS database as described above. The background
promoter sequences were generated with genes that were not regulated by
insulin in the microarray experiment (1000 probe sets). Unique promoters for
750 unregulated genes were retrieved from DBTSS based on the same selection
criterion for insulin-regulated genes. The Clover program [46] was used to
predict the overrepresented motifs using 795 position weight matrices from the
Professional TRANSFAC 10.1 database. The Clover analysis parameters were
set at 1000 randomizations and a p-value cutoff of 0.01.Acknowledgments
We thank Brian Bates, Steve Haney, and Andrew Lake
for advice and discussion and Andrew Hill, Padma Reddy,
Yizheng Li, and Maryann Whitley for technical assistance. We
also acknowledge Ruth Gimeno for critical review of the
manuscript.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.ygeno.2006.10.006.
References
[1] L.C. Cantley, The phosphoinositide 3-kinase pathway, Science 296 (2002)
1655–1657.
[2] L.E. Rameh, L.C. Cantley, The role of phosphoinositide 3-kinase lipid
products in cell function, J. Biol. Chem. 274 (1999) 8347–8350.[3] J. Kalesnikoff, L.M. Sly, M.R. Hughes, T. Buchse, M.J. Rauh, L.P. Cao, V.
Lam, A. Mui, M. Huber, G. Krystal, The role of SHIP in cytokine-induced
signaling, Rev. Physiol., Biochem. Pharmacol. 149 (2003) 87–103.
[4] T. Sasaoka, H. Hori, T. Wada, M. Ishiki, T. Haruta, H. Ishihara, M.
Kobayashi, SH2-containing inositol phosphatase 2 negatively regulates
insulin-induced glycogen synthesis in L6 myotubes, Diabetologia 44
(2001) 1258–1267.
[5] T. Wada, T. Sasaoka, M. Funaki, H. Hori, S. Murakami, M. Ishiki, T.
Haruta, T. Asano, W. Ogawa, H. Ishihara, M. Kobayashi, Overexpression
of SH2-containing inositol phosphatase 2 results in negative regulation of
insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5(-phos-
phatase catalytic activity, Mol. Cell. Biol. 21 (2001) 1633–1646.
[6] K. Fukui, T. Wada, S. Kagawa, K. Nagira, M. Ikubo, H. Ishihara, M.
Kobayashi, T. Sasaoka, Impact of the liver-specific expression of SHIP2
(SH2-containing inositol 5′-phosphatase 2) on insulin signaling and
glucose metabolism in mice, Diabetes 54 (2005) 1958–1967.
[7] X. Tang, A.M. Powelka, N.A. Soriano, M.P. Czech, A. Guilherme, PTEN,
but not SHIP2, suppresses insulin signaling through the phosphatidylino-
sitol 3-kinase/Akt pathway in 3T3-L1 adipocytes, J. Biol. Chem. 280
(2005) 22523–22529.
[8] S. Clement, U. Krause, F. Desmedt, J. Tanti, J. Behrends, X. Pesesse,
Corrigendum: the lipid phosphatase SHIP2 controls insulin sensitivity,
Nature 431 (2004) 878.
[9] S. Clement, U. Krause, F. Desmedt, J.F. Tanti, J. Behrends, X. Pesesse, T.
Sasaki, J. Penninger, M. Doherty, W. Malaisse, J.E. Dumont, Y. Le March-
Brustel, C. Erneux, L. Hue, S. Schurmans, The lipid phosphatase SHIP2
controls insulin sensitivity, Nature 409 (2001) 92–97.
[10] M.W. Sleeman, K.E. Wortley, K.M. Lai, L.C. Gowen, J. Kintner, W.O.
Kline, K. Garcia, T.N. Stitt, G.D. Yancopoulos, S.J. Wiegand, D.J. Glass,
Absence of the lipid phosphatase SHIP2 confers resistance to dietary
obesity, Nat. Med. 11 (2005) 199–205.
[11] P.J. Kaisaki, M. Delepine, P.Y. Woon, L. Sebag-Montefiore, S.P. Wilder, S.
Menzel, N. Vionnet, E. Marion, J.P. Riveline, G. Charpentier, S.
Schurmans, J.C. Levy, M. Lathrop, M. Farrall, D. Gauguier, Polymor-
phisms in type II SH2 domain-containing inositol 5-phosphatase (INPPL1,
SHIP2) are associated with physiological abnormalities of the metabolic
syndrome, Diabetes 53 (2004) 1900–1904.
[12] H. Hori, T. Sasaoka, H. Ishihara, T. Wada, S. Murakami, M. Ishiki, M.
Kobayashi, Association of SH2-containing inositol phosphatase 2 with
the insulin resistance of diabetic db/db mice, Diabetes 51 (2002)
2387–2394.
[13] E. Marion, P.J. Kaisaki, V. Pouillon, C. Gueydan, J.C. Levy, A. Bodson, G.
Krzentowski, J.C. Daubresse, J. Mockel, J. Behrends, G. Servais, C.
Szpirer, V. Kruys, D. Gauguier, S. Schurmans, The gene INPPL1,
encoding the lipid phosphatase SHIP2, is a candidate for type 2 diabetes in
rat and man, Diabetes 51 (2002) 2012–2017.
[14] S. Kagawa, T. Sasaoka, S. Yaguchi, H. Ishihara, H. Tsuneki, S. Murakami,
K. Fukui, T. Wada, S. Kobayashi, I. Kimura, M. Kobayashi, Impact of
SRC homology 2-containing inositol 5′-phosphatase 2 gene polymorph-
isms detected in a Japanese population on insulin signaling, J. Clin.
Endocrinol. Metab. 90 (2005) 2911–2919.
[15] J.M. Dyson, C.J. O’Malley, J. Becanovic, A.D. Munday, M.C. Berndt, I.D.
Coghill, H.H. Nandurkar, L.M. Ooms, C.A. Mitchell, The SH2-containing
inositol polyphosphate 5-phosphatase, SHIP-2, binds filamin and regulates
submembraneous actin, J. Cell Biol. 155 (2001) 1065–1079.
[16] N. Paternotte, J. Zhang, I. Vandenbroere, K. Backers, D. Blero, N. Kioka,
J.M. Vanderwinden, I. Pirson, C. Erneux, SHIP2 interaction with the
cytoskeletal protein Vinexin, FEBS J. 272 (2005) 6052–6066.
[17] N. Prasad, R.S. Topping, S.J. Decker, SH2-containing inositol 5′-
phosphatase SHIP2 associates with the p130(Cas) adapter protein and
regulates cellular adhesion and spreading, Mol. Cell. Biol. 21 (2001)
1416–1428.
[18] N. Prasad, R.S. Topping, S.J. Decker, Src family tyrosine kinases regulate
adhesion-dependent tyrosine phosphorylation of 5′-inositol phosphatase
SHIP2 during cell attachment and spreading on collagen I, J. Cell Sci. 115
(2002) 3807–3815.
[19] N.K. Prasad, S.J. Decker, SH2-containing 5′-inositol phosphatase, SHIP2,
regulates cytoskeleton organization and ligand-dependent down-regulation
279C. Huard et al. / Genomics 89 (2007) 270–279of the epidermal growth factor receptor, J. Biol. Chem. 280 (2005)
13129–13136.
[20] T. Sasaoka, K. Kikuchi, T. Wada, A. Sato, H. Hori, S. Murakami, K. Fukui,
H. Ishihara, R. Aota, I. Kimura, M. Kobayashi, Dual role of SRC
homology domain 2-containing inositol phosphatase 2 in the regulation of
platelet-derived growth factor and insulin-like growth factor I signaling in
rat vascular smooth muscle cells, Endocrinology 144 (2003) 4204–4214.
[21] Y. Wang, R.J. Keogh, M.G. Hunter, C.A. Mitchell, R.S. Frey, K. Javaid,
A.B.Malik, S. Schurmans, S. Tridandapani, C.B.Marsh, SHIP2 is recruited
to the cell membrane upon macrophage colony-stimulating factor (M-CSF)
stimulation and regulates M-CSF-induced signaling, J. Immunol. 173
(2004) 6820–6830.
[22] X. Pesesse, S. Deleu, F. De Smedt, L. Drayer, C. Erneux, Identification of a
second SH2-domain-containing protein closely related to the phosphati-
dylinositol polyphosphate 5-phosphatase SHIP, Biochem. Biophys. Res.
Commun. 239 (1997) 697–700.
[23] R.M. O’Brien, D.K. Granner, Regulation of gene expression by insulin,
Physiol. Rev. 76 (1996) 1109–1161.
[24] R.M. O’Brien, R.S. Streeper, J.E. Ayala, B.T. Stadelmaier, L.A.
Hornbuckle, Insulin-regulated gene expression, Biochem. Soc. Trans. 29
(2001) 552–558.
[25] P.H. Ducluzeau, N. Perretti, M. Laville, F. Andreelli, N. Vega, J.P. Riou, H.
Vidal, Regulation by insulin of gene expression in human skeletal muscle
and adipose tissue: evidence for specific defects in type 2 diabetes,
Diabetes 50 (2001) 1134–1142.
[26] S. Rome, K. Clement, R. Rabasa-Lhoret, E. Loizon, C. Poitou, G.S. Barsh,
J.P. Riou, M. Laville, H. Vidal, Microarray profiling of human skeletal
muscle reveals that insulin regulates approximately 800 genes during a
hyperinsulinemic clamp, J. Biol. Chem. 278 (2003) 18063–18068.
[27] R. Sreekumar, P. Halvatsiotis, J.C. Schimke, K.S. Nair, Gene expression
profile in skeletal muscle of type 2 diabetes and the effect of insulin
treatment, Diabetes 51 (2002) 1913–1920.
[28] V.K. Yechoor, M.E. Patti, R. Saccone, C.R. Kahn, Coordinated patterns of
gene expression for substrate and energy metabolism in skeletal muscle of
diabetic mice, Proc. Natl. Acad. Sci. USA 99 (2002) 10587–10592.
[29] X. Li, P.A. Hansen, L. Xi, R.A. Chandraratna, C.F. Burant, Distinct
mechanisms of glucose lowering by specific agonists for peroxisomal
proliferator activated receptor gamma and retinoic acid X receptors, J. Biol.
Chem. 280 (2005) 38317–38327.
[30] C.C. Bastie, Z. Nahle, T. McLoughlin, K. Esser, W. Zhang, T. Unterman,
N.A. Abumrad, FoxO1 stimulates fatty acid uptake and oxidation in muscle
cells through CD36-dependent and -independent mechanisms, J. Biol.
Chem. 280 (2005) 14222–14229.
[31] T.F. Tzeng, I.M. Liu, J.T. Cheng, Activation of opioid mu-receptors by
loperamide to improve interleukin-6-induced inhibition of insulin signals
in myoblast C2C12 cells, Diabetologia 48 (2005) 1386–1392.
[32] Y. Matsuoka, X. Li, V. Bennett, Adducin: structure, function and
regulation, Cell. Mol. Life Sci. 57 (2000) 884–895.
[33] J.M. Falcon-Perez, M. Starcevic, R. Gautam, E.C. Dell’Angelica, BLOC-1, a novel complex containing the pallidin and muted proteins involved in
the biogenesis of melanosomes and platelet-dense granules, J. Biol. Chem.
277 (2002) 28191–28199.
[34] R. Efendiev, R.T. Krmar, G. Ogimoto, J. Zwiller, G. Tripodi, A.I. Katz, G.
Bianchi, C.H. Pedemonte, A.M. Bertorello, Hypertension-linked mutation
in the adducin alpha-subunit leads to higher AP2-mu2 phosphorylation and
impaired Na+,K+-ATPase trafficking in response to GPCR signals and
intracellular sodium, Circ. Res. 95 (2004) 1100–1108.
[35] K. Tsuchida, T. Matsuzaki, N. Yamakawa, Z. Liu, H. Sugino, Intracellular
and extracellular control of activin function by novel regulatory molecules,
Mol. Cell. Endocrinol. 180 (2001) 25–31.
[36] L. Huang, Y.M. Kuo, J. Gitschier, The pallid gene encodes a novel,
syntaxin 13-interacting protein involved in platelet storage pool deficiency,
Nat. Genet. 23 (1999) 329–332.
[37] A. Greka, B. Navarro, E. Oancea, A. Duggan, D.E. Clapham, TRPC5 is a
regulator of hippocampal neurite length and growth cone morphology, Nat.
Neurosci. 6 (2003) 837–845.
[38] S. Noguchi, M. Fujita, K. Murayama, R. Kurokawa, I. Nishino, Gene
expression analyses in X-linked myotubular myopathy, Neurology 65
(2005) 732–737.
[39] A. Buj-Bello, V. Laugel, N. Messaddeq, H. Zahreddine, J. Laporte, J.F.
Pellissier, J.L. Mandel, The lipid phosphatase myotubularin is essential for
skeletal muscle maintenance but not for myogenesis in mice, Proc. Natl.
Acad. Sci. USA 99 (2002) 15060–15065.
[40] J. Laporte, F. Blondeau, A. Gansmuller, Y. Lutz, J.L. Vonesch, J.L.
Mandel, The PtdIns3P phosphatase myotubularin is a cytoplasmic protein
that also localizes to Rac1-inducible plasma membrane ruffles, J. Cell Sci.
115 (2002) 3105–3117.
[41] A. Kotlyarov, Y. Yannoni, S. Fritz, K. Laass, J.B. Telliez, D. Pitman, L.L.
Lin, M. Gaestel, Distinct cellular functions of MK2, Mol. Cell. Biol. 22
(2002) 4827–4835.
[42] A.A. Hill, E.L. Brown, M.Z. Whitley, G. Tucker-Kellogg, C.P. Hunter,
D.K. Slonim, Evaluation of normalization procedures for oligonucleotide
array data based on spiked cRNA controls, Genome Biol. 2 (2001)
(RESEARCH0055).
[43] M.B. Eisen, P.T. Spellman, P.O. Brown, D. Botstein, Cluster analysis and
display of genome-wide expression patterns, Proc. Natl. Acad. Sci. USA
95 (1998) 14863–14868.
[44] Y. Suzuki, R. Yamashita, S. Sugano, K. Nakai, DBTSS, DataBase of
Transcriptional Start Sites: progress report 2004, Nucleic Acids Res. 32
(2004) D78–D81.
[45] V. Matys, O.V. Kel-Margoulis, E. Fricke, I. Liebich, S. Land, A. Barre-
Dirrie, I. Reuter, D. Chekmenev, M. Krull, K. Hornischer, N. Voss, P.
Stegmaier, B. Lewicki-Potapov, H. Saxel, A.E. Kel, E. Wingender,
TRANSFAC and its module TRANSCompel: transcriptional gene
regulation in eukaryotes, Nucleic Acids Res. 34 (2006) D108–D110.
[46] M.C. Frith, Y. Fu, L. Yu, J.F. Chen, U. Hansen, Z. Weng, Detection of
functional DNA motifs via statistical over-representation, Nucleic Acids
Res. 32 (2004) 1372–1381.
